Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALG-055009 in Non-Cirrhotic Adults With Metabolic Dysfunction-Associated Steatohepatitis

NCT06342947 is registered in ClinicalTrials.gov with Aligos Therapeutics as lead sponsor.

NCT NCT06342947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06342947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALG-055009 in Non-Cirrhotic Adults With Metabolic Dysfunction-Associated Steatohepatitis
Lead sponsor
Aligos Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
April 1, 2024
Completion date
September 9, 2024
Enrollment
102 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

mash, metabolic dysfunction-associated steatohepatitis, nash, nonalcoholic steatohepatitis